"Promising Breast Cancer Vaccine Offers Hope for Aggressive Form of the Disease"
Anixa Biosciences is developing a potentially game-changing vaccine that could prevent the recurrence of the most aggressive form of breast cancer, triple-negative breast cancer. The vaccine, developed by the late Dr. Vincent Tuohy, is currently being tested on women diagnosed with this type of breast cancer. If successful, the vaccine could hit the market within the next five years. The team has received FDA approval to begin human testing in 2021 and is currently conducting a trial with promising results. The goal is to eventually test the vaccine on women with other types of breast cancer and explore its potential for cancer prevention in those who have never had the disease.
